WFRF:(Radua J)
Sökning: WFRF:(Radua J) > (2021) > Efficacy and safety...
Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis
-
- Lee, H. J. (författare)
- Yonsei Univ, South Korea,CIBERSAM, Spain; Univ Versailles St Quentin en Yvelines, France
-
- Jeong, G. H. (författare)
- Gyeongsang Natl Univ, South Korea,Med Univ Innsbruck, Austria; Tyrolean Canc Res Inst, Austria
-
- Li, H. (författare)
- Univ Florida, FL USA
- visa fler...
- Cargnin, S. (författare)
- visa färre...
- (creator_code:org_t)
- VERDUCI PUBLISHER, 2021
- 2021
- Engelska.
- Ingår i: European Review for Medical and Pharmacological Sciences. - : VERDUCI PUBLISHER. - 1128-3602 .- 2284-0729. ; 25:20, s. 6232-6244
- Forskningsöversikt (refereegranskat)
Abstract
Ämnesord
Stäng
- OBJECTIVE: It is controversial whether there is efficacy or safety benefit of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non small cell lung cancer (NSCLC) compared to standard chemotherapy. We aim to assess the efficacy and safety of EGFR-TKIs compared to another chemotherapeutics in EGFR-mutated NSCLC. MATERIALS AND METHODS: Up to April 27th, 2020, PubMed, Embase, Medline, Scopus, Cochrane library, and ClinicalTrials.gov were searched for articles or trials meeting the inclusion criteria. After filtering, 230 eligible studies were initially identified. Data extraction followed PRISMA and included outcomes were progression-free survival (PFS), overall survival (OS), and severe adverse events (SAEs). Direct and indirect meta-analyses were generated in the context of log-linear mixed-effects models, with fixed effects for each relative comparison and random effects for each study. RESULTS: The results showed that EGFR-TKI therapy had improved PFS with a hazard ratio (HR) of 0.40 (95% CI: 0.36-0.44, p<0.001) compared to standard chemotherapy. Nevertheless, the EGFR-TKIs showed no benefit on OS (HR: 0.96, 95% CI: 0.83-1.10, p=0.556). In the analysis of adverse events, EGFR-TKIs had fewer SAEs than standard chemotherapy (HR: 0.29, 95% CI: 0.26-0.33, p<0.001). CONCLUSIONS: Our systemic review indicates that EGFR-TKI therapy has improved PFS, and reduced SAEs compared to standard chemotherapy in advanced EGFR-mutated NSCLC.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Non-small cell lung cancer; Epidermal growth factor receptor; Tyrosine kinase; Meta-analysis
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
- European Review for Medical and Pharmacological Sciences (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
Hitta mer i SwePub
- Av författaren/redakt...
- Lee, H. J.
- Jeong, G. H.
- Li, H.
- Kim, M. S.
- Kim, J. S.
- Park, S. J.
- visa fler...
- Han, Y. J.
- Lee, K. H.
- Kronbichler, A.
- Hong, S. H.
- Ghayda, R. A.
- Luchini, C.
- Nottegar, A.
- Koyanagi, A.
- Smith, L.
- Jacob, L.
- Dragioti, Elena
- Radua, J.
- Cargnin, S.
- Terrazzino, S.
- Thompson, T.
- Yon, D. K.
- Lee, S. W.
- Yang, J. M.
- Wasuwanich, P.
- Shin, J. I.
- Gamerith, G.
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- European Review ...
- Av lärosätet
- Linköpings universitet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
